The Expanding Role of the Pharmacist in HIV PreventionWhat Do You Know About PrEP?
HIV providers’ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report.
Adams LM, Balderson BH. AIDS Care. 2016;28(9):1154-1158.
Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.
Bruno C, Saberi P. Int J Clin Pharm. 2012;34(6):803-806.
Centers for Disease Control and Prevention, 2017.
Centers for Disease Control and Prevention, 2012.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.
Copenhaver MM, et al. J Subst Abuse Treat. 2006;31(2):163-171.
Darin KM, et al. J Am Pharm Assoc (2003). 2015;55(1):81-88.
Integrating antiretroviral strategies for human immunodeficiency virus prevention: post- and pre-exposure prophylaxis and early treatment.
Grant RM, Smith DK. Open Forum Infect Dis. 2015;2(4):ofv126.
Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599.
Grey J, Emory Coalition for Applied Modeling for Prevention (CAMP).
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
McCormack S, et al. Lancet. 2016;387(10013):53-60.
PrEP REP project.
Exploratory survey of Florida pharmacists' experience, knowledge, and perception of HIV pre-exposure prophylaxis.
Shaeer KM, et al. J Am Pharm Assoc (2003). 2014;54(6):610-617.
PrEP: HIV Pre-Exposure Prophylaxis
Narrated by Richard A. Elion, MD
What Do You Know About PrEP?
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
Informing the Future of NASH Diagnosis and Assessment
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice